Skip to Main Content

There’s a popular theory about the limitations of global pharma companies: For all their skyscrapers and strategy reviews and private jets, they’re simply too knotted up in bureaucracy to realize how many great drugs are gathering dust in their vaults.

Now, the biggest of Big Pharma is out do do something about that. Pfizer, home to nearly 100,000 employees, on Monday announced the launch of a six-person startup to develop new drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • How about they make it a non-profit. That way the bottom line will be saving lives and not shareholder profit.

  • As long as the scientists (and management) of these startups are selected with the same criteria scientists are hired at big pharma companies, nothing revolutionary or innovative will ever come out of them

    • Dear Agbo, you should disclose that you work for the home team. LOL

      As I read that clinical stage drugs are the center of it, the only innovation I see here is just finding others willing to foot the bill of the clinical trials. So, no brains and scientific skills required.
      And the fact that Pfizer is not really interested to invest in them, it suggests there is a good chance that the investors will qualify as fools/suckers

Comments are closed.